Abstract 417P
Background
Soft tissue sarcomas belong to a heterogeneous group of malignant tumours of mesenchymal origin which constitutes <1% of adult cancers and 12% of paediatric cancers. This study highlights the clinical spectrum of sarcomas, various histological patterns and survival outcomes. The intent is to study retrospectively the clinicopathologic profile and survival outcomes of soft tissue sarcomas and bone sarcomas treated with radiation therapy at a Regional Cancer Centre from South India.
Methods
The clinical and treatment details of patients were collected retrospectively for the period 2014 -2017 and were analysed using descriptive statistics. Survival analysis was done using Kaplan-Meir Analysis.
Results
The median age of presentation was 42 years (Range 2-80). Among the 123 patients studied , 54.5%(n = 67) were males and 45.5%(n = 56) were females. The most common presenting complaint was swelling 69% (n = 85) followed by pain 38.2% (n = 47). The most common site of involvement was extremity 48% (n = 59). Other more commonly involved sites were Genitourinary 7.3%(n = 9) and uterus 4.9% (n = 6). The most common histology was Ewing Sarcoma 14.6%(n = 18) followed by Undifferentiated Pleomorphic Sarcoma 13.8% (n = 17). Around 17.9%(n = 22) had metastatic disease at presentation, of which metastasis to lungs (n = 13) was most common, followed by bone (n = 8) and liver(n = 4). The intent of Radiation Therapy was Adjuvant 54.4%(n = 67), Palliative 32.2%(n = 21), Radical 13.8 (n = 17) and Neoadjuvant 6.5%(n = 8). Only 65.9%(n = 81) completed their intended radiation therapy. 91.9% (n = 113) received External Beam Radiation Therapy and 13% (n = 16) received Brachytherapy. Around 48.8% (n = 60) underwent surgery and 66.6% (n = 82) received some form of chemotherapy. The Mean Overall Survival was 50.4 months (95% CI 44.2-56.5 months). Median OS was not reached.
Conclusions
As per our study, the most common histology was Ewing Sarcoma, followed by Undifferentiated Pleomorphic sarcoma. Approximately 70% of sarcoma patients referred to Radiation Oncology department were for Curative intent whereas 30% with palliative intent and this has led to Mean OS of 50.4 months. At the same time with limited follow up data and the low number of events, the Median OS was not reached.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
274P - Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene
Presenter: Raimkul Karakulov
Session: Poster display session
Resources:
Abstract
275P - Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam
Presenter: Gia Nguyen Hoang
Session: Poster display session
Resources:
Abstract
276P - Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis
Presenter: GEDALA Veni Prasanna
Session: Poster display session
Resources:
Abstract
277P - Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia
Presenter: Zeeshan Ahmed
Session: Poster display session
Resources:
Abstract
278P - A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma
Presenter: Gautamjeet Mangat
Session: Poster display session
Resources:
Abstract
280P - Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL
Presenter: Kundan Mishra
Session: Poster display session
Resources:
Abstract
281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
Presenter: Jing Sun
Session: Poster display session
Resources:
Abstract
282P - Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling
Presenter: Nidh Gupta
Session: Poster display session
Resources:
Abstract
283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis
Presenter: Jinhyun Cho
Session: Poster display session
Resources:
Abstract